NASDAQ: SSKN 3Q 2023 Earnings Conference Call and Webcast | November 14, 2023

Forward Looking Statements 2 This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell an acne treatment device and to integrate that device into its product offerings, the Company’s ability to develop, launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to dermatologist marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the coronavirus and political factors or conditions affecting the Company and the medical device industry in general, future responses to and effects of COVID-19 pandemic and its variants including the distribution and effectiveness of the COVID-19 vaccines, as well as more specific risks and uncertainties set forth in the Company’sSECreports on Forms 10-Q and 10-K. Givensuch uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this presentation are made as of the date of this presentation, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this presentation. The Company urges investors to carefully review itsSECdisclosures available at www.sec.gov and www.strataskinsciences.com.

Third Quarter 2023 Highlights Comparative 3Q Revenues (Dollars in thousands) Three Months Ended Nine Months Ended 3Q 2022 3Q 2023 $0 $2,000 $4,000 $6,000 $8,000 $10,000 Dr. Dolev Rafaeli was named the new Vice-Chairman, President and CEO Placed 81 TheraClear®X devices as of September 30, 2023 Non-GAAP EBITDA improved 67% to $1.0M compared to $0.6M YoY 3Q 2022 3Q 2023 $0 $5,000 $10,000 $15,000 $20,000 $25,000 $30,000 $9,413 3 $8,852 $25,559 $24,469

Total Revenue (Dollars in thousands) Balance Sheet $8.5M cash & cash equivalents* Increased YoY from additional proceeds from refinancing Senior Term Facility on June 30, 2023 Annualized Financials 2020 2021 2022 2023* $0 $10,000 $20,000 $30,000 $40,000 $23,090 *As of September 30, 2023. 4 $29,977 $36,161 $24,699

Domestic International 3Q 2022 3Q 2023 $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 3Q 2022 3Q 2023 $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 Revenue Mix *As of September 30, 2023. 5 $6,099 $3,314 $5,839 $3,013 $5,280 $3,566 $5,847 $3,572

3Q 2022 4Q 2022 1Q 2023 2Q 2023 3Q 2023 $-1,000 $-500 $0 $500 $1,000 $1,500 Three Months Ended Comparison (In thousands) Improved 21% YoY 6 Non-GAAP Adjusted EBITDA Continued improvement to net loss over periods from G&A, S&M reduction

DTC Marketing Clinical Support Customer Support Reimbursement Support* Co-pay Assistance Field Service Support Consumables and Parts Laser Upgrades* A True Partnership Delivering a Complete Business Solution *Reimbursement Support and Laser Upgrades only applies to XTRAC® 7

IN-HOUSE CALL CENTER 8 VERIFY XTRAC TREATMENT REOCCURRENCE ASSIGNING A DOCTOR PARTNER PATIENT APPOINTMENT TREATMENT INSURANCE ADVOCACY WIN-WIN-WIN DOCTOR+PATIENT+PAYER Domestic XTRAC Revenue Funnel DTC ADVERTISING VERIFY APPOINTMENT INTEREST CREATION DTC expands Patient Leads Patient Leads turn into Appointments and create a halo effect in clinics Appointments drive revenue: XTRAC partners and partner clinics STRATA

Leads Appointments RDX Charts (New Patient Charts) 2018 2019 2020 2021 2022 2023* 0 10,000 20,000 30,000 40,000 50,000 * Thru October 2023 Patient Leads Drive Recurring Sales 21,939 4,011 18,733 47,429 6,203 22,711 19,223 2,729 15,555 33,164 4,896 21,332 19,698 2,830 15,965 177 38 9,973 Recurring Revenue model in practice. Pandemic reduces in-person appointments, company pivots to device sales over recurring model. Device sales model stays in tact as pandemic eases. 9 1 2 3 Leads, Appointments, RDX Charts

Average Recuring Revenue/Device Domestic Strategy Core Business Refocused to Recurring Revenue US Installed Base 746 820 832 898 909 929 $7,055 $7,209 $5,062 $5,906 $5,923 $5,235 2022 2023* *As of October 31, 2023. 2018 2019 2020 2021 2022 2023* 2018 2019 2020 2021 US Recurring Revenue Growth Achieved Through: Renewed focus on direct-to-consumer initiatives to drive recurring revenue Strategically positioned to achieve pre-pandemic Revenue per Unit (RPU) 10

Closing Remarks Reallocating advertising spending to prioritize DTC Redirecting TheraClearX from the aesthetics market to the medical market Reigniting the customer experience and value to our clinical partners 11

Q&A Session